CD36 and atrial fibrillation: Pretreatment with anti‐CD36 antibody or Annexin V decreased platelet activation induced by AF‐MV, as assessed by PAC‐1 binding (P < .05) (Figure 4A, B and D) and secretion of P‐selectin (P < .05) (Figure 4E).